‘Worth the Risk,’ Says Investor About UnitedHealth Stock

UnitedHealth (UNH) shares have declined roughly 9% recently after a brief rally, extending year-to-date losses to approximately 42% amid an earnings miss, CEO departure, withdrawn guidance due to rising medical costs, and a DOJ investigation into Medicare fraud. Despite these headwinds, one investor, Daniel Schönberger, maintains a Buy rating, citing the company's fundamental strength, long-term growth prospects, and recession-proof nature, projecting a 10.61% EPS compound annual growth between fiscal 2024 and 2034; the consensus among Wall Street analysts is a Moderate Buy with a $380.59 average price target, suggesting a 29% upside.

Analysis

UnitedHealth (UNH) has experienced significant stock price pressure, with shares declining approximately 9% over the last three trading sessions despite a brief insider-buying-fueled rally, contributing to a year-to-date drop of around 42%. This downturn follows a confluence of negative catalysts, including a rare earnings miss in mid-April—the first since 2008—where revenue fell short by over $2 billion. Further compounding investor concerns, May saw the abrupt departure of CEO Andrew Witty, the withdrawal of full-year guidance due to escalating medical care activities and costs, and reports of a U.S. Department of Justice investigation into potential Medicare fraud. Despite these substantial headwinds and fragile sentiment, some market participants, like investor Daniel Schönberger, perceive an opportunity, citing UNH's fundamental strength, robust long-term growth prospects, stable margins, and a proven economic moat. Schönberger highlights the company's historical revenue growth of 843% between 2005 and 2025 (as stated in the article) and its resilience, with 99% of revenues sourced from the U.S. and the healthcare sector's typically recession-proof nature. Projections cited suggest a compound annual EPS growth of 10.61% between fiscal 2024 and 2034, with company management reportedly even more optimistic, expecting 13% to 16% EPS growth. This bullish outlook is somewhat echoed by Wall Street, where UNH carries a Moderate Buy consensus rating based on 19 Buys, 6 Holds, and 1 Sell, with an average 12-month price target of $380.59, implying a potential upside of approximately 29% from current levels. The overall market impact score of 0.6 and a moderately positive sentiment score of 0.35 suggest that despite the negatives, the presented bullish arguments carry weight.

Key Decisions for Investors

• Investors should carefully weigh the significant recent adverse events, including the earnings miss, CEO change, withdrawn guidance, and DOJ investigation, against the company's historically strong fundamentals and optimistic long-term growth projections from analysts and certain investors.
• Given the substantial 42% year-to-date share price decline, value-oriented or contrarian investors might consider the current valuation, supported by an average analyst price target suggesting a ~29% upside, as a potential entry point, acknowledging the heightened risks.
• Prudent investors should closely monitor upcoming earnings reports, updates on medical cost trends, any further guidance from new management, and the resolution of the DOJ investigation, as these factors will be critical in determining UNH's ability to navigate current challenges and realize its projected growth.